2,367 Shares in Natera, Inc. $NTRA Purchased by SteelPeak Wealth LLC

SteelPeak Wealth LLC acquired a new position in Natera, Inc. (NASDAQ:NTRA) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,367 shares of the medical research company’s stock, valued at approximately $473,000.

Several other large investors have also modified their holdings of NTRA. Horizon Investments LLC raised its holdings in shares of Natera by 22.0% in the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after acquiring an additional 45 shares during the last quarter. Savvy Advisors Inc. boosted its holdings in Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after acquiring an additional 46 shares during the period. First Horizon Corp boosted its holdings in Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 51 shares during the period. Finally, Siemens Fonds Invest GmbH grew its position in Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after acquiring an additional 54 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their target price on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. UBS Group set a $260.00 price target on shares of Natera in a report on Wednesday, June 24th. Royal Bank Of Canada started coverage on shares of Natera in a research note on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price target on the stock. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Finally, Guggenheim upped their target price on shares of Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $267.83.

Natera Trading Up 0.6%

Shares of NTRA stock opened at $271.39 on Friday. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $288.04. The stock has a fifty day simple moving average of $233.97 and a two-hundred day simple moving average of $220.41. The stock has a market capitalization of $38.87 billion, a price-to-earnings ratio of -166.50 and a beta of 1.51.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 41,124 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at $24,035,465.29. This represents a 27.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Herm Rosenman sold 16,530 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the sale, the director directly owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,872 shares of company stock valued at $39,627,696 over the last three months. 5.05% of the stock is currently owned by corporate insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.